AAKP's role in Clinical Trials and Market Research
AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice and experience with renal companies and clinical trials - to create more and better treatment options for kidney patients, so they can achieve their aspirations.
You may have heard the term “clinical trials” but wonder what that means. Is a clinical trial something you can participate in? What do you need to do to get started? We have pulled together some information that you might find helpful as you decide whether you would like to participate in a clinical trial.
View our Clinical Trial Brochure
Learn More About AAKP Awareness Campaigns
Understanding Clinical Research: A Guide for Patients and Caregivers (Source: The American Society of Nephrology's (ASN) Kidney Health Initiative (KHI))
Clinical Trials and Market Research Opportunities
Below is a list of the Clinical Trials and Market Research opportunities that AAKP is partnering to raise awareness of. You can also use the search tool below to be matched to even more opportunities.
| Name | Description | Learn More |
|---|---|---|
| aXess Pivotal Clinical Trial | The aXess US Pivotal trial is a prospective, single arm, multi-center study to evaluate the safety and performance of the aXess graft in adult patients with ESKD who need hemodialysis. aXess is an innovative vascular access device that is designed to initially function as a synthetic graft but progressively transforms into a living blood vessel. aXess is designed to potentially reduce infection and reintervention rates compared to existing AVGs and to improve vascular access options in ESKD patients. | Click here to read more about this opportunity. |
| CONCORD (AMR after Kidney Transplant) | The CONCORD Study is a clinical research study for people who have received a kidney transplant and are experiencing antibody-mediated rejection (AMR). AMR is a common cause of kidney transplant rejection that can lead to transplant failure. This study is evaluating a potential new medication, ALXN2030, to see if it can help treat AMR by changing how the immune system responds, compared to a placebo. All participants will continue to receive standard kidney transplant care, in addition to receiving either ALXN2030 or a placebo as a subcutaneous injection. The study involves regular health checkups, blood and urine tests, and ongoing support from the research team. | Click here to read more about this opportunity. |
| AUTUMN | Brief description: The AUTUMN Study is a clinical research study for people with primary membranous nephropathy (PMN), a rare kidney condition that can cause swelling in your lower body, fatigue, and changes in urine. This study is investigating a potential new treatment, ALXN1920, to see if it can help protect the kidneys and prevent disease progression, compared to a placebo. Everyone in the study receives standard PMN care while also receiving either ALXN1920 or a placebo as a weekly infusion for about six months, with regular checkups and support from the study team. | Click here to read more about this opportunity. |
| I CAN | Brief description: The I CAN Study is a Phase III clinical research trial for adults with immunoglobulin A nephropathy (IgAN). The study is testing ravulizumab (ULTOMIRIS®) to see if it can protect kidney function and slow disease progression, compared to a placebo. Participants can keep receiving standard IgAN care while getting either ravulizumab or placebo by IV infusion every eight weeks for about two years, with regular checkups and support from the study team. | Click here to read more about this opportunity. |
| I CAN Junior | Brief description: This study is for children and teens (ages 2 to under 18) who have been diagnosed with immunoglobulin A nephropathy (IgAN) or IgA vasculitis-related kidney disease (IgAVN). The goal of this clinical trial is to learn if a medicine called ravulizumab (ULTOMIRIS®) can help protect kidneys and lower protein levels in the urine, which means slowing down or stopping kidney damage. Everyone in the study will get ravulizumab by IV infusion, alongside their regular kidney medicine. The infusions happen on a schedule based on the child’s weight, with regular checkups and lab tests for about two years. The study team will be there to support participants and answer questions throughout the process. | Click here to read more about this opportunity. |
| AWAKE Study | Brief description: The primary goal of this study is to avoid the chance of the kidney not immediately working or never working at all after a transplant. If a newly transplanted kidney does not work after five to seven days, then dialysis is needed until the kidney starts working. The study will try to prevent DGF so that the new kidney can “wake up” and immediately work after transplant. | Click here to read more about this opportunity. |
| PROACT 1 | The ProKidney PROACT 1 study is a Phase 3 clinical trial testing an investigational cell therapy product called rilparencel, which is prepared from a patient’s own kidney cells. The goal of the study is to assess whether rilparencel can stabilize kidney function and delay progression to end-stage kidney disease in patients with advanced CKD and Type 2 diabetes. | Click here to read more about this opportunity. |
| PREVAIL (IgAN) | PREVAIL is a clinical study to learn more about the effect of felzartamab on proteinuria (too much protein in the urine) and the kidneys’ ability to filter blood in adults with IgAN. | Click here to read more about this opportunity. |
| PROMINENT (PMN) | PROMINENT is a clinical study to learn more about the effect of felzartamab on the buildup of antibodies in the filters (glomeruli) of the kidneys in adults diagnosed with primary membranous nephropathy, known as PMN. | Click here to read more about this opportunity. |
| DYADS sample collection study | Join the DYADS sample collection study to help develop and validate an investigational non-invasive test that assesses whether an unborn baby may be affected by ARPKD. Participation involves collecting blood and/or cheek swab samples and health information from both the biological female parent who is a carrier and their biological children. The investigational test is being developed to be used during pregnancy for people who are carriers of certain genetic conditions who want to help determine whether their unborn baby may have inherited a genetic condition. Your participation in this study is critical to expanding the future of prenatal genetic screening and helping more families plan for their children’s future. | Click here to read more about this opportunity. |
| HIB-202-101 Lupus Nephritis Study | This clinical research study is testing an investigational medication for adults with lupus nephritis. The goal of the study is to see if the study medication can help with symptoms of lupus nephritis and stop the condition from getting worse. | Click here to read more about this opportunity. |
| KYSA-1 | The KYSA-1 trial is designed to evaluate if Chimeric Antigen Receptor (CAR) T-cell therapy is safe in people who have active lupus nephritis (LN) and do not get better with standard therapies. CAR T-cell therapy is a type of treatment called immunotherapy. This means it works with your immune system to target B cells in your body. Unhealthy B cells drive inflammation and disease activity in LN. | Click here to read more about this opportunity. |
| SAFE Kidney II | The purpose of this study is to evaluate the safety, tolerability, and efficacy of AntiBKV in reducing BK viremia and progression to biopsy-confirmed BKVAN in Kidney Transplant Recipients (KTRs). The study includes two parts. The phase II part will evaluate the safety of AntiBKV in KTRs and establish proof of concept. The phase III part will assess the efficacy of AntiBKV in KTRs. | Click here to read more about this opportunity. |
| ConfIdeS | Protocol 20-HMedIdeS-17/ ConfIdeS: An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care. The study is for End-Stage Renal Disease (ESRD) patients that are highly sensitized and are active on the OPTN waiting list for a kidney transplant. | Click here to read more about this opportunity. |
